Kaifeng Jin

1.1k total citations
34 papers, 608 citations indexed

About

Kaifeng Jin is a scholar working on Oncology, Surgery and Immunology. According to data from OpenAlex, Kaifeng Jin has authored 34 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Surgery and 15 papers in Immunology. Recurrent topics in Kaifeng Jin's work include Cancer Immunotherapy and Biomarkers (27 papers), Bladder and Urothelial Cancer Treatments (23 papers) and Immune Cell Function and Interaction (9 papers). Kaifeng Jin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Bladder and Urothelial Cancer Treatments (23 papers) and Immune Cell Function and Interaction (9 papers). Kaifeng Jin collaborates with scholars based in China and Japan. Kaifeng Jin's co-authors include Jiejie Xu, Zhaopei Liu, Yu Zhu, Han Zeng, Le Xu, Chao Lin, Hongyong He, Zewei Wang, Kunpeng Lv and Yun Gu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Surgery and Clinical Cancer Research.

In The Last Decade

Kaifeng Jin

30 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaifeng Jin China 12 325 320 196 174 115 34 608
Yifan Cao China 14 290 0.9× 249 0.8× 175 0.9× 136 0.8× 79 0.7× 29 529
Hanji Fang China 13 310 1.0× 278 0.9× 151 0.8× 123 0.7× 62 0.5× 20 509
Zhilan Xiao China 13 326 1.0× 268 0.8× 177 0.9× 196 1.1× 116 1.0× 21 651
Kunpeng Lv China 14 271 0.8× 274 0.9× 142 0.7× 109 0.6× 48 0.4× 19 484
Takayuki Ninomiya Japan 8 272 0.8× 147 0.5× 165 0.8× 153 0.9× 133 1.2× 17 531
Paul-Yang Lin Taiwan 7 227 0.7× 159 0.5× 124 0.6× 74 0.4× 99 0.9× 8 404
Budiman Kharma Japan 10 335 1.0× 273 0.9× 165 0.8× 60 0.3× 38 0.3× 12 577
Zoila A. Lopez‐Bujanda United States 11 409 1.3× 291 0.9× 275 1.4× 197 1.1× 32 0.3× 18 731
Rishab Ramapriyan United States 9 320 1.0× 158 0.5× 215 1.1× 177 1.0× 43 0.4× 18 598
Jonathan E. Schoenhals United States 14 457 1.4× 322 1.0× 124 0.6× 253 1.5× 76 0.7× 22 744

Countries citing papers authored by Kaifeng Jin

Since Specialization
Citations

This map shows the geographic impact of Kaifeng Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaifeng Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaifeng Jin more than expected).

Fields of papers citing papers by Kaifeng Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaifeng Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaifeng Jin. The network helps show where Kaifeng Jin may publish in the future.

Co-authorship network of co-authors of Kaifeng Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Kaifeng Jin. A scholar is included among the top collaborators of Kaifeng Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaifeng Jin. Kaifeng Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zhaopei, Kaifeng Jin, Han Zeng, et al.. (2025). ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. Clinical Cancer Research. 31(20). 4311–4322. 1 indexed citations
2.
3.
Jin, Kaifeng, Zhaopei Liu, Han Zeng, et al.. (2025). Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression. Journal for ImmunoTherapy of Cancer. 13(1). e010964–e010964. 1 indexed citations
4.
5.
Li, Bingyu, Kaifeng Jin, Zhaopei Liu, et al.. (2024). Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer. Cancer Immunology Immunotherapy. 73(4). 66–66. 2 indexed citations
6.
Liu, Ge, Kaifeng Jin, Zhaopei Liu, et al.. (2024). POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1. Cancer Medicine. 13(4). e6962–e6962. 4 indexed citations
7.
Jin, Kaifeng, Ziyue Xu, Bingyu Li, et al.. (2024). TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma. The Journal of Pathology. 263(2). 139–149. 4 indexed citations
8.
Liu, Ge, Kaifeng Jin, Zhaopei Liu, et al.. (2024). Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science. 115(4). 1306–1316. 3 indexed citations
9.
Shao, Fei, Kaifeng Jin, Bingyu Li, et al.. (2023). Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 41(10). 433.e9–433.e18. 2 indexed citations
10.
Liu, Zhaopei, Kaifeng Jin, Ziyue Xu, et al.. (2023). Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation. SHILAP Revista de lepidopterología. 2(1). e000199–e000199. 3 indexed citations
11.
Liu, Zhaopei, Kaifeng Jin, Han Zeng, et al.. (2022). B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. European Journal of Cancer. 171. 133–142. 11 indexed citations
12.
Jin, Shengming, Han Zeng, Zhaopei Liu, et al.. (2022). Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology. 29(4). 2495–2503. 4 indexed citations
13.
Liu, Zhaopei, Han Zeng, Kaifeng Jin, et al.. (2022). TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. British Journal of Cancer. 126(9). 1310–1317. 14 indexed citations
14.
Zeng, Han, Kaifeng Jin, Zhaopei Liu, et al.. (2022). Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Cancer Immunology Immunotherapy. 71(9). 2117–2126. 2 indexed citations
15.
Liu, Zhaopei, Kaifeng Jin, Han Zeng, et al.. (2022). Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. British Journal of Cancer. 127(9). 1718–1725. 2 indexed citations
16.
Jin, Kaifeng, Han Zeng, Zhaopei Liu, et al.. (2022). CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. British Journal of Cancer. 126(11). 1581–1588. 28 indexed citations
17.
Zeng, Han, Zhaopei Liu, Kaifeng Jin, et al.. (2021). Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Cancer Immunology Immunotherapy. 71(2). 301–310. 4 indexed citations
18.
Sun, Mengmeng, Han Zeng, Kaifeng Jin, et al.. (2021). Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology Immunotherapy. 71(6). 1497–1506. 25 indexed citations
19.
Zeng, Han, Zhaopei Liu, Kaifeng Jin, et al.. (2021). Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients. Urologic Oncology Seminars and Original Investigations. 40(3). 109.e11–109.e20. 3 indexed citations
20.
Fang, Hanji, Yun Gu, Yuchao Fei, et al.. (2020). Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. OncoImmunology. 9(1). 1856468–1856468. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yifan Cao Breakdown of academic impact, for papers by Hanji Fang Breakdown of academic impact, for papers by Zhilan Xiao Breakdown of academic impact, for papers by Kunpeng Lv Breakdown of academic impact, for papers by Takayuki Ninomiya Breakdown of academic impact, for papers by Paul-Yang Lin Breakdown of academic impact, for papers by Budiman Kharma Breakdown of academic impact, for papers by Zoila A. Lopez‐Bujanda Breakdown of academic impact, for papers by Rishab Ramapriyan Breakdown of academic impact, for papers by Jonathan E. Schoenhals
Rankless by CCL
2026